These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

It is possible to mimic the effect of GLP-1 in the body to boost weight loss with the right kind of diet. Read weight loss ...

Novon Nordisk's Ozempic/Wigobi, a glucagon-like peptide-1 (GLP-1) injection, and Eli Lilly's Mounjaro/Jebbound have been ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

SHOPPING: Achieve your weight goals in 2025 with help from this potent polyphenol blend that boosts your natural production ...

The Oral Proteins And Peptides market report covers market characteristics, size and growth, segmentation, regional and ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...

Figuring out if GLP-1s are the right fit for you isn’t something to tackle alone—and that’s where Mochi Health comes in.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...